The experience of weight loss and its associated burden in patients with non‐small cell lung cancer: results of an online survey

Rodríguez, Ana María; Braverman, Julia; Aggarwal, Dimple; Friend, John; Duus, Elizabeth Manning

doi:10.17987/jcsm-cr.v2i2.18

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of confounding variables, for example, other comorbid diseases and presence of TKI adverse effects, may likewise influence the subsequent PS. Weight loss is said to be a prognostic factor of diminished survival, decreased quality of life and more symptoms in lung cancer patients 18,19 .…”

Section: Discussionmentioning

confidence: 99%

Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients

Maranatha¹,

Wulandari²,

Soegiarto³

2021

IJFMT

View full text Add to dashboard Cite

Objective: To compare the response of first-generation EGFR-TKI (epidermal growth factor receptortyrosine kinase inhibitors) in non-small cell lung cancer (NSCLC) patients with single common and uncommon EGFR mutation. Methods:Patients were divided into two groups, the uncommon (exon 21 L861Q, exon 18 G719X, exon 18 delE709) and common EGFR mutation group (exon 19 deletion, exon 21 L858R). Health-related quality of life (HRQOL) using EuroQol EQ-5D ® questionnaire, body weight, performance status (PS), Response Evaluation Criteria in Solid Tumors (RECIST) on chest CT, progression-free survival (PFS) and overall survival (OS) was recorded during TKI therapy. Results:The value of HRQOL was stable and PS was constant in both groups, body weight was constant in uncommon group (42.1%) and increased in common group (44.1%; p=0.165). The uncommon group showed mostly progressive disease in RECIST (47.4%) while the common group showed mostly partial response (42.2%; p=0.007). PFS in the uncommon group was 4 (2.0-6.0) months and 7.0 (2.0-21.0) months in the common group (p=0.001). OS in the uncommon and common group were 4.00±1.71 months and 10.00±6.94 months (p<0.001), respectively. Conclusion:NSCLC patients with common EGFR mutations showed a better response and survival rate compared to uncommon EGFR mutations on first-generation TKI therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients

Maranatha¹,

Wulandari²,

Soegiarto³

2021

IJFMT

View full text Add to dashboard Cite

show abstract

“…Remune is high in the omega‐3 fatty acids EPA/DHA and vitamin D and is a source of protein. The product is suitable for patients with precachexia and cachexia who are not able to get sufficient amounts of these nutrients through their normal diet, such as patients with COPD or cancer. Remune is a milk‐based drink and includes 226 kcal, 10 g protein, omega 3, and 10 μg Vitamin D. A total of 45 patients with moderate to severe COPD with involuntary weight loss receive either Targeted Medical Nutrition (Remune, Smartfish) or isocaloric comparator twice daily for 12 weeks.…”

Section: Clinical Trials and Newly Treatment Targetsmentioning

confidence: 99%

Silver linings on the horizon: highlights from the 10th Cachexia Conference

Ebner

Haehling

2018

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

This article highlights the updates from preclinical and clinical studies into the field of wasting disorders that were presented at the 10th Cachexia Conference held in Rome, Italy, in December 2017. This year's conference saw some interesting results of larger‐scale studies and clinical trials and new therapeutic targets. Herein, we summarize the biological and clinical significance of different markers and new diagnostic tools and cut‐offs for the detection of skeletal muscle wasting, including micro RNAs, the ubiquitin‐proteasome system, mTOR signalling, news in body composition analysis including the D3‐creatine dilution method, and new biomarkers. Clinical studies investigated novel nutritional approaches, trials of elamipretide, enobosarm, and urolithin A. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.

show abstract

“…2 These patients often suffer from multiple different co-morbidities that may develop as consequences from anti-cancer therapies. Frequent problems include, but are not limited to, chronic kidney disease, 3,4 liver dysfunction, 5,6 gastrointestinal disease, 7,8 anaemia, 9,10 fatigue, 11,12 infections, 13,14 anorexia 15,16 , muscle wasting, 17,18 pain, 19,20 and heart failure (HF). 21,22 Depending on the cancer diagnosis and the type of anti-cancer treatment, cardiotoxicity rates may vary from 0% to 48% of patients, with HF being a predominant presentation.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

et al. 2019

View full text Add to dashboard Cite

While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

show abstract

The experience of weight loss and its associated burden in patients with non‐small cell lung cancer: results of an online survey

Abstract: Background: The main objectives of this study were to characterize and compare the burden of non-small cell lung cancer (NSCLC) patients reporting considerable unintentional weight loss (≥ 5% in the past 6 months or ≥ 2% for a BMI < 20 kg/m

Cited by 7 publications

References 29 publications

Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients

Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients

Silver linings on the horizon: highlights from the 10th Cachexia Conference

Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

Contact Info

Product

Resources

About